Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02348190 · ClinicalTrials.gov registry record · NA

Fat Induced Insulin Resistance and Atherosclerosis

A NA study, sponsored by Temple University.

Completed
Registry status
NA
Development phase
86
Enrollment target

NCT02348190 is a NA study that has completed, run by Temple University. The registered enrollment target is 86 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02348190, a NA study, has completed, sponsored by Temple University.

COMPLETED
Registry status
NA
Development phase
86 participants
Enrollment target

Study Summary

The overall objective of the current proposal is to strengthen the putative link between FFA induced insulin resistance and atherosclerotic vascular disease (ASVD). To this end, the investigators will test the following hypotheses: 1) that FFA induced activation of protein kinase C βII (PKC β II) and δ and other serine kinases such as IκB kinase (IKK) in human muscle is associated with a decrease in insulin stimulated tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1) and of IRS-1 associated phosphatidylinositol 3 (PI3) kinase; 2) that these changes precede the development of insulin resistance; 3) that the decrease in IκB-α results in activation of nuclear factor κB (NFκB) and the expression of adhesion molecules and cytokines; 4) that PKC and IKK are involved in producing insulin resistance and activation of the IκB/ NFκB pathway and lastly 5) that the same mechanisms operative in healthy volunteers are also operative in patients with T2DM.The investigators will test these hypotheses in normal (current) and diabetic volunteers (previously completed) . Euglycemic-hyperinsulinemic clamps will be performed with and without co-infusion of lipid plus heparin (to raise FFAs) and by obtaining serial muscle and fat biopsies and blood samples will be obtained for measurement of substrates, hormones, enzymes and metabolites.

Interventions

  • OTHER Lipid/heparin

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2003-06
Est. Completion 2015-06
Phase NA

Sponsor

Temple University

163 total trials

What the Registry Record Tells You About NCT02348190

The ClinicalTrials.gov registry entry for NCT02348190 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Lipid/heparin is the first listed.

NCT02348190 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02348190 about?

NCT02348190 is a clinical study titled "Fat Induced Insulin Resistance and Atherosclerosis". The overall objective of the current proposal is to strengthen the putative link between FFA induced insulin resistance and atherosclerotic vascular disease (ASVD). To this end, the investigators will test the following hypotheses: 1) that FFA induced activation of protein kinase C βII (PKC β II) an...

What is the current status of trial NCT02348190?

This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2003-06. Estimated completion is 2015-06.

What interventions are being tested in trial NCT02348190?

The interventions under investigation include: Lipid/heparin (OTHER).

Who is sponsoring clinical trial NCT02348190?

This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.